-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Bangshun Pharmaceutical's Hong Kong Stock IPO Prospectus Expires

Zhitongcaijing·07/22/2026 01:25:02
Listen to the news

The Zhitong Finance App learned that the Hong Kong stock prospectus submitted by Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical for short) on January 22, 2026 expired for 6 months and expired on July 22, 2026. CITIC Construction Investment International is its sole sponsor.

image.png

According to the prospectus, Bangshun Pharmaceutical is a biotechnology company focusing on the field of cancer and autoimmune diseases. The company has established a pipeline covering a new drug application (NDA) stage candidate (bezexitinib), a registered clinical-stage drug candidate (CX1440), and five pre-clinical stage drug candidates (CX03, CX12, CX13, CX15 and CX16).